Newsfeeds - Spark Newswire

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

Today, 12:58 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABBV

1 minute read

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67

By Benzinga Newsdesk

Today, 12:58 PM

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $55 to $67.

APLS

1 minute read

Analyst Ratings

Where Apellis Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 12:58 PM

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:

APLS

1 minute read

Analyst Ratings

Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here’s What You Need To Know

By Benzinga Insights

Today, 12:58 PM

Stifel has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from $60.00 to $65.00. Shares of Apellis Pharmaceuticals are trading up 2.69% over the last 24 hours, at $65.98 per share.

APLS

1 minute read

Moderna To $165? Plus This Analyst Cuts PT On FedEx

By Lisa Levin

Today, 12:58 PM

Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to trade at $138.70 on Thursday.

AEO

2 minute read

Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday

By Lisa Levin

Today, 12:58 PM

U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session.

AAP

2 minute read

Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 12:58 PM

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene…

AIMD

1 minute read

Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study

By Ragothaman Srinivasan

Today, 12:58 PM

Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

APLS